XNAS · Healthcare · Biotechnology
HCW Biologics Inc is a clinical-stage biopharmaceutical company developing transformative fusion immunotherapeutics to support or treat diseases promoted by chronic inflammation. It has created novel compounds that represent a new class of drugs that it believes has the potential to fundamentally change the treatment of autoimmune disorders and other proinflammatory diseases, cancer and senescence-associated dysplasia. The company has developed two proprietary drug discovery and development platforms which it uses to create novel fusion immunotherapeutics: The TOBI (Tissue factOr-Based fusIon) platform, and The T-cell Receptor Beta Chain constant region (TRBC) platform. It operates and manages its business as one reportable segment.
| Date | Period | EPS Est. | EPS Act. | Surprise | Revenue | Result | 1D Δ | 1W Δ | 1M Δ |
|---|---|---|---|---|---|---|---|---|---|
| 2026-05-14 | Q1 2026 | -0.44 | 0.37 | +184.09% | $6.5M | ✅ Beat | +122.55% | +665.58% | — |
| 2026-03-31 | Q4 2025 | -0.84 | -1.02 | -21.43% | $27,010 | ❌ Miss | -7.92% | -24.17% | +30.89% |
| 2025-11-14 |
| Q3 2025 |
| 1.58 |
| -2.02 |
| -227.85% |
| $15.6M |
| ❌ Miss |
| — |
| — |
| — |
| 2025-08-18 | Q2 2025 | -2.30 | -6.79 | -195.22% | $6,550 | ❌ Miss | +1.47% | +38.06% | +7.21% |
| 2025-03-28 | Q4 2024 | — | -0.08 | — | $394,804 | — | -5.97% | -24.27% | -38.33% |
| 2024-11-14 | Q3 2024 | — | -0.10 | — | $426,423 | — | -4.66% | +129.64% | +15.18% |
| 2024-08-14 | Q2 2024 | — | -0.40 | — | $618,854 | — | -13.62% | -26.02% | +5.17% |
| 2024-05-15 | Q1 2024 | — | -0.20 | — | $1.1M | — | -5.17% | -4.32% | -3.45% |
Showing last 8 quarters.